Trials / Completed
CompletedNCT00891748
Safety Study on AdCD40L Gene Therapy for Bladder Cancer
A Phase I/IIa Study of Dose-escalating Intravesical AdCD40L Instillation in Urinary Bladder Carcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Uppsala University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study objective is to evaluate the feasibility of three instillations of immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer. Tolerance, toxicity and immunological parameters will be evaluated during and post treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | AdCD40L | Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2009-10-01
- Completion
- 2009-10-01
- First posted
- 2009-05-01
- Last updated
- 2010-01-18
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00891748. Inclusion in this directory is not an endorsement.